Compare ARVN & STKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | STKL |
|---|---|---|
| Founded | 2015 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 768.2M |
| IPO Year | 2018 | 1999 |
| Metric | ARVN | STKL |
|---|---|---|
| Price | $8.96 | $6.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 3 |
| Target Price | ★ $15.05 | $7.50 |
| AVG Volume (30 Days) | 854.3K | ★ 855.4K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 58.84 | ★ 186.67 |
| EPS | N/A | ★ 0.13 |
| Revenue | $262,600,000.00 | ★ $817,715,000.00 |
| Revenue This Year | N/A | $6.84 |
| Revenue Next Year | N/A | $33.58 |
| P/E Ratio | ★ N/A | $49.96 |
| Revenue Growth | N/A | ★ 12.99 |
| 52 Week Low | $6.06 | $3.32 |
| 52 Week High | $14.22 | $6.94 |
| Indicator | ARVN | STKL |
|---|---|---|
| Relative Strength Index (RSI) | 35.45 | 64.45 |
| Support Level | $7.35 | $6.43 |
| Resistance Level | $10.18 | $6.51 |
| Average True Range (ATR) | 0.51 | 0.02 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 23.34 | 62.50 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
SunOpta Inc is a Canadian company that focuses on a healthy product portfolio. The company is a manufacturer for natural and private label brands and also produces its own proprietary brands, including SOWN, Dream, and West Life. The core of its product portfolio is a range of plant-based beverages, including oat, almond, soy, coconut, and rice milks and creamers, which have a favorable climate profile relative to traditional dairy milks in terms of lower carbon emissions and water usage. Their plant-based offerings include non-genetically modified, organic, and gluten-free products. The consumer products portfolio also includes protein shakes, teas, broths, and fruit snacks. Geographically, the company operates in U.S, Canada, and Others, out of which it derives maximum revenue from U.S.